Reported 2 days ago
Pfizer Inc. has concluded a global licensing agreement with 3SBio, granting it exclusive rights to develop and commercialize a bispecific antibody, SSGJ-707, targeting PD-1 and VEGF. This deal, which includes a $1.25 billion initial payment, aims to enhance Pfizer's oncology pipeline with promising clinical trials for non-small cell lung cancer and gynecological tumors currently underway in China. Pfizer also has the option to extend exclusive rights in China, marking a strategic move to strengthen its position in cancer research.
Source: YAHOO